BJDX vs IDXX

IDEXX Laboratories, Inc.

(IDXX) offers the better valuation at 43. 7x trailing P/E (39. 5x forward), making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +5. 1%, compared to -100. 0% for Bluejay Diagnostics, Inc. (BJDX). Over 10 years, the gap is even starker: IDXX returned +556. 2% versus BJDX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bluejay Diagnostics, Inc.

(BJDX) is the lower-risk stock at 0. 89β versus IDEXX Laboratories, Inc. 's 1. 35β — meaning IDXX is approximately 51% more volatile than BJDX relative to the S&P 500. On balance sheet safety, Bluejay Diagnostics, Inc. (BJDX) carries a lower debt/equity ratio of 4% versus 67% for IDEXX Laboratories, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Bluejay Diagnostics, Inc.

grew EPS 42. 1% year-over-year, compared to 22. 6% for IDEXX Laboratories, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus 0. 0% for Bluejay Diagnostics, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus 0. 0% for BJDX. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+556. 2% 10Y return). Both have compounded well over 10 years (IDXX: +556. 2%, BJDX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.